ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)
Authors
Keywords
-
Journal
XENOBIOTICA
Volume -, Issue -, Pages 1-44
Publisher
Informa UK Limited
Online
2022-10-31
DOI
10.1080/00498254.2022.2141667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Free Drug Theory – No Longer Just a Hypothesis?
- (2022) Scott G. Summerfield et al. PHARMACEUTICAL RESEARCH
- Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice
- (2022) Hsuan-Ping Chang et al. PHARMACEUTICAL RESEARCH
- Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics
- (2022) Ruipeng Mu et al. BIODRUGS
- Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
- (2022) Shujun Dong et al. Frontiers in Pharmacology
- Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates
- (2022) Kai H. Liao et al. AAPS Journal
- Characterization of Antibody–Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM
- (2021) Yue Huang et al. ANALYTICAL CHEMISTRY
- Model Informed Therapeutic Dose Optimization Strategies for Antibody‐Drug Conjugates (ADCs) in Oncology: What Can We Learn from FDA‐Approved ADCs?
- (2021) Michael Z. Liao et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
- (2021) Ophelia Yin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Antibody‒drug conjugates: Recent advances in linker chemistry
- (2021) Zheng Su et al. Acta Pharmaceutica Sinica B
- Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody–drug conjugates
- (2021) Andrew P Mayer et al. Bioanalysis
- Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective
- (2021) Chunze Li et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2–Positive Tumors
- (2021) Bruna Menezes et al. DRUG METABOLISM AND DISPOSITION
- Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates
- (2021) Eshita Khera et al. MOLECULAR CANCER THERAPEUTICS
- An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
- (2021) Juliana T. W. Tong et al. MOLECULES
- Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method
- (2021) Seo-jin Park et al. Applied Sciences-Basel
- Dose Predictions for Drug Design
- (2020) Tristan S. Maurer et al. JOURNAL OF MEDICINAL CHEMISTRY
- An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics
- (2020) David W Meyer et al. MOLECULAR PHARMACEUTICS
- Evolution of the Systems PK-PD Model for Antibody-drug Conjugates (ADC) to Characterize Tumor Heterogeneity and In Vivo Bystander Effect
- (2020) Aman P Singh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine
- (2020) Weize Huang et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates
- (2020) Xiaoyu Zhu et al. Journal of Pharmaceutical Analysis
- Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
- (2020) Alison Betts et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades
- (2020) Michael Davies et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
- (2020) Eshita Khera et al. NEOPLASIA
- A method to directly analyze free-drug–related species in antibody-drug conjugates without sample preparation
- (2019) Niluka de Mel et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
- (2019) Donglu Zhang et al. DRUG METABOLISM AND DISPOSITION
- Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance
- (2019) Maria Jove et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry
- (2019) Ling Xu et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
- (2018) Ajit Suri et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- “Standing by” for Bystander Effects: Dual Isotope Imaging of Antibody-Drug Conjugate and Payload Distribution
- (2018) Cornelius Cilliers et al. JOURNAL OF NUCLEAR MEDICINE
- Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates
- (2018) Balázs Bobály et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Enrichment of protein therapeutics and biomarkers for LC–MS quantification
- (2018) Jie Pu et al. Bioanalysis
- LC–MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
- (2017) Yazhong Liu et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)
- (2016) Aman P. Singh et al. AAPS Journal
- Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
- (2016) Cornelius Cilliers et al. AAPS Journal
- Custom-Designed Affinity Capture LC-MS F(ab′)2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates
- (2016) Dian Su et al. ANALYTICAL CHEMISTRY
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Characterization of antibody–drug conjugates by mass spectrometry: advances and future trends
- (2016) Richard Y.-C. Huang et al. DRUG DISCOVERY TODAY
- Unconjugated payload quantification and DAR characterization of antibody–drug conjugates using high-resolution MS
- (2016) Leanne Grafmuller et al. Bioanalysis
- Imaging mass spectrometry for the precise design of antibody-drug conjugates
- (2016) Yuki Fujiwara et al. Scientific Reports
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans
- (2015) Haiqing Wang et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
- (2015) Christina Vasalou et al. PLoS One
- A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
- (2014) Brendan Bender et al. AAPS Journal
- Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates
- (2014) Russ Wada et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer
- (2014) J Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Model-based drug discovery: implementation and impact
- (2013) Sandra A.G. Visser et al. DRUG DISCOVERY TODAY
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
- (2013) Nahor Haddish-Berhane et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum
- (2013) Keyang Xu et al. Bioanalysis
- Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper
- (2013) Boris Gorovits et al. Bioanalysis
- Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics
- (2013) Surinder Kaur et al. Bioanalysis
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry
- (2011) Keyang Xu et al. ANALYTICAL BIOCHEMISTRY
- A sensitive LC–MS/MS method for the determination of free maytansinoid DM4 concentrations—Method development, validation, and application to the nonclinical studies of antitumor agent DM4 conjugated hu-anti-Cripto MAb B3F6 (B3F6-DM4) in rats and monkeys
- (2011) Dong Wei et al. INTERNATIONAL JOURNAL OF MASS SPECTROMETRY
- PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach
- (2011) Patrick Poulin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
- (2011) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Analytical methods for physicochemical characterization of antibody drug conjugates
- (2011) Aditya Wakankar et al. mAbs
- Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates
- (2011) Jean Philippe Stephan et al. Bioanalysis
- Prediction of Exposure–Response Relationships to Support First-in-Human Study Design
- (2010) John P. Gibbs AAPS Journal
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
- (2010) Nelson L. Jumbe et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
- (2010) Dennis A. Smith et al. NATURE REVIEWS DRUG DISCOVERY
- Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids
- (2008) G. M. Thurber et al. CANCER RESEARCH
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search